Discover and read the best of Twitter Threads about #PharmEasy

Most recents (4)

🚨Welcome to a new edition of #FullStack by @samidhas, a place where you’ll find unfiltered commentary on all things technology. Read on 👇
#Edtech major #Byju's is faced with a trifecta of issues. There is the $1.2 billion TLB (term loan B), delayed audited results, and an equity funding round which has been in the works for months now
On Tuesday, #Byju’s defaulted on interest payment of $40 million for its term loan. That was not all, the beleaguered edtech firm said it is suing hedge fund Redwood, one of its lenders.

economictimes.indiatimes.com/tech/technolog…
Read 8 tweets
Dr. Velumani onboard with 5% .

Aditya Puri inducted into the board and my guess will me made Chairman soon .

Founder( Siddharth Shah’s ) parents have tasted failure & succeeded.

FY22 Revenue : 6500 Cr.

Peak of Pessimism priced in ? Mostly.

#UL2 Image
IPO only when it’s just 3-6 months away from hitting EBITDA Positive .

This one is a B2B + B2C + B2B2C bet .

Also it’s Diagnostics arm is smartly playing the Tier 3 & Tier 4 - BHARAT 🇮🇳 theme .

#Thyrocare #Pharmeasy
My Scuttlebutt revealed peak of TECH employee firing done by last December . Now realistic numbers have settled in .

Definitely 2022 has been a year of reevaluation ( maybe all thanks to Zomato, Nykaa & PolicyBazaars of the world)

$9 BN. to $6 BN. to where ? 😃
Read 8 tweets
Pharmeasy IPO (API Holdings IPO)

#pharmeasy #apiholdings #pharmeasyipo

A thread on the key takeaways from DHRP .....

IPO expected in Feb 2021

investmentbank.kotak.com/downloads/api-… Image
The parent company of PharmEasy, API Holdings, has filed for its DRHP with SEBI on 08th Nov for a fresh issue of ₹6,250cr ($830m) value equity shares and there is no offer for sale (OFS) by the promoters.

They are also looking for a pre-IPO placement of ₹1,250 cr in this issue
Objectives of the issue
1. Repay its outstanding debt of ₹1,930cr
2. Fund organic growth initiatives ₹1,260cr (marketing and promotional activities, supply chain and ramp up technology infra)
3. Fund inorganic growth initiatives ₹1,500cr
4. Corporate purposes ₹1,560cr
Read 22 tweets
#Pharmeasy - Health Tech #unicorn – to acquire Majority stake (66%) in #Thyrocare. Open offer for an additional 26% stake at Rs1300/sh. With this diagnostics bet, it completes its exhaustive portfolio of "Wholistic Outpatient Healthcare Ecosystem". (1/9) Image
Gujju Gang from Ghatkopar (as founders call themselves) make it big in what is first-ever acquisition of publicly listed firm by the unicorn. New funding tied up at #valuations of USD4bn. Promoters of Thyrocare will also be investing in Pharmeasy for 5% stake. (2/9)
Pharmeasy founders started as venture called dialhealth.com (2012-13) which failed, followed by Dial Health chain of retail stores which also failed. After 2 failed ventures, they moved to distribution business (& B2B) that was a success (2015). (3/9)
Read 9 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!